Abstract
While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.
Keywords: dorsal root ganglia, Nrf2 protein, hyperglycemia, oxidative stress, advanced glycation products
Current Drug Targets
Title: The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Volume: 9 Issue: 1
Author(s): Andrea M. Vincent, James L. Edwards, Mahdieh Sadidi and Eva L. Feldman
Affiliation:
Keywords: dorsal root ganglia, Nrf2 protein, hyperglycemia, oxidative stress, advanced glycation products
Abstract: While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.
Export Options
About this article
Cite this article as:
Vincent M. Andrea, Edwards L. James, Sadidi Mahdieh and Feldman L. Eva, The Antioxidant Response as a Drug Target in Diabetic Neuropathy, Current Drug Targets 2008; 9 (1) . https://dx.doi.org/10.2174/138945008783431754
DOI https://dx.doi.org/10.2174/138945008783431754 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New and Investigational Antimicrobials for the Treatment of Severe Skin Infections
Current Drug Therapy Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation The Antidiabetic Potential of Quercetin: Underlying Mechanisms
Current Medicinal Chemistry Flavonoids as Potential Therapeutic Agents for the Management of Diabetic Neuropathy
Current Pharmaceutical Design Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Schiff Bases of Istain: Antiglycation Activity
Letters in Drug Design & Discovery Host Genomics Plasticity in Response to Ambient Temperature Change: Transcriptional Regulation Induced by Cold Temperature Perception in the Human BEAS-2B Cell Line
Current Pharmacogenomics and Personalized Medicine Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Advanced Glycation: Implications in Tissue Damage and Disease
Protein & Peptide Letters Topical Analgesics in Neuropathic Pain
Current Pharmaceutical Design Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity:Role of Sympathetic Nerve Activity and Insulin Resistance
Current Diabetes Reviews Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders